Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Prestazioni e risultati relativi all'udito negli adulti a cui è stato impiantato l'impianto cocleare a eluizione di desametasone CI622D rispetto a quelli impiantati con un impianto cocleare standard (CI622) (DETECT)

5 ottobre 2026 aggiornato da: Cochlear

Uno studio cruciale, prospettico, multicentrico, controllato randomizzato, in cieco per la valutazione dell'efficacia di un elettrodo dritto sottile a eluizione di desametasone (CI622D) nella riduzione dell'impedenza rispetto a un elettrodo dritto sottile standard (CI622) in una popolazione adulta appena impiantata con Perdita dell'udito neurosensoriale post-linguistica, bilaterale, da moderatamente grave a profonda.

This clinical study will test a newly developed cochlear implant known as CI622D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation, which is common after any surgical procedure. The goal is to learn if there are added benefits in implant performance and hearing outcomes with the dexamethasone-releasing cochlear implant (CI622D) vs. the standard cochlear implant (CI622) without dexamethasone. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve. The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing ability and their overall general health.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Effettivo)

50

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • New South Wales
      • Sydney, New South Wales, Australia
        • Westmead Private Hospital
      • Sydney, New South Wales, Australia
        • Royal Prince Alfred Hospital
      • Sydney, New South Wales, Australia
        • Macquarie University
    • Victoria
      • Melbourne, Victoria, Australia
        • St Vincent Private Hospital
      • Melbourne E., Victoria, Australia
        • Royal Victorian Eye and Ear Hospital
      • Lille, Francia
        • Centre Hospitalier Universitaire de Lille
      • Paris, Francia
        • Hôpital Universitaire Pitié-Salpêtrière
      • Toulouse, Francia
        • Centre Hospitalier Universitaire Toulouse
    • Freiburg Im Breisgau
      • Freiburg im Breisgau, Freiburg Im Breisgau, Germania
        • Universitätsklinikum Freiburg
    • Lower Saxony
      • Hanover, Lower Saxony, Germania
        • Medizinische Hochschule Hannover
      • Manchester, Regno Unito
        • Manchester Royal Infirmary

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Aged 18 years or older (at time of consent)
  • Clinically established post-linguistic bilateral moderately severe to profound sensorineural hearing loss
  • Meets local candidacy criteria for cochlear implantation
  • Compromised functional hearing with a hearing aid in the ear to be implanted
  • Willing to participate in and comply with all requirements of the protocol, including willingness to be randomised to either arm
  • Evidence of pneumococcal vaccination (e.g., Pneumovax) according to local guidelines prior to randomisation
  • Candidate is proficient in the language used to assess speech perception performance
  • Willing and able to provide written informed consent.

Exclusion Criteria:

  • Planned for a partial insertion of the electrode array
  • Intra-axial (within the brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted
  • Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment
  • Active autoimmune disease or active immunosuppressive therapy
  • Any of the following in the ear to be implanted within 3 months prior to enrolment: history of prior otologic surgery including grommets, or tympanic membrane perforation
  • Previously reported diagnosis of auditory neuropathy, in the ear to be implanted
  • Previously reported diagnosis, in the ear to be implanted, of Large Vestibular Aqueduct Syndrome (LVAS), Meniere's disease, or cochlear hydrops
  • Ossification, otosclerosis, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by imaging, in the ear to be implanted
  • Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, temporo- parietal skull fracture or CSF leaks
  • History of bacterial meningitis
  • Known allergic reaction or contraindication to dexamethasone or corticosteroids
  • Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the subject
  • Severe, or poorer, sensorineural hearing loss of more than 20 years, as reported by the subject, in the ear to be implanted
  • Prior cochlear implantation, in either ear
  • Medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted
  • Medical or psychological conditions that contraindicate general anaesthesia, surgery or participation in the clinical investigation, as determined by the investigator
  • Women who are pregnant
  • Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices as determined by the Investigator
  • Additional disabilities that may affect the subject's participation or safety during the clinical investigation, as determined by the Investigator
  • Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator
  • Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as spouse, parent, child, or sibling to the study candidate
  • Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation
  • Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by investigator or Sponsor to not impact this investigation)
  • Subjects recruited at a French site who are not affiliated with social security
  • Subjects recruited at a French site who are under legal protection.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: CI622D

Investigational Medical Device (IMD)

A dexamethasone-eluting Slim Straight electrode

Comparatore attivo: CI622

An approved medical device

A standard Slim Straight electrode

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Difference in the mean impedance between CI622D and CI622
Lasso di tempo: 6 months post-activation

Mean monopolar impedance measured across the active electrodes of the implant for each participant.

6 months post-activation

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of Treatment-Emergent Adverse Events of the CI622D and CI622
Lasso di tempo: Throughout study (12 months)

Percentage of the number of participants who experience an adverse event for the CI622D group and the CI622 group

Throughout study (12 months)
Difference in the proportion of participants with preservation of low frequency residual hearing with CI622D compared with CI622
Lasso di tempo: Pre-implantation to 6 months post activation

The proportion of participants achieving ≤ 30 dB change in the low frequency pure tone average (LFPTA) (250 Hz and 500 Hz). This measure will be applied to the subgroup of participants who have a LFPTA < 80 dB HL at the pre-operative baseline.

Pre-implantation to 6 months post activation
Mean change (within-subject) in word recognition score in the preferred unilateral listening mode in quiet with the CI622D
Lasso di tempo: Pre-implantation to 6 months post-activation

Change in percent correct word recognition score

Pre-implantation to 6 months post-activation
Mean change (within-subject) in word recognition score in the preferred bilateral listening mode in quiet with the CI622D
Lasso di tempo: Pre-implantation to 6 months post-activation

Change in percent correct word recognition score

Pre-implantation to 6 months post-activation
Difference in mean (within-subject) change in word recognition score in the preferred unilateral listening mode in quiet with the CI622D compared with CI622
Lasso di tempo: Pre-implantation to 12 months post-activation

Change in percent correct word recognition score

Pre-implantation to 12 months post-activation
Difference in mean (within-subject) change in word recognition score in the preferred bilateral listening mode in quiet from pre-implantation to post-activation with CI622D compared with CI622
Lasso di tempo: Pre-implantation to 12 months post-activation

Change in percent correct word recognition score

Pre-implantation to 12 months post-activation
Difference in mean (within-subject) change in sentence recognition score in noise in the preferred unilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622
Lasso di tempo: Pre-implantation to 12 months post-activation

Change in percent correct sentence recognition score (Matrix test + 10 SNR)

Pre-implantation to 12 months post-activation
Difference in mean (within-subject) change in sentence recognition score in noise in the preferred bilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622
Lasso di tempo: Pre-implantation to 12 months post-activation

Change in percent correct sentence recognition score (Matrix test + 10 SNR)

Pre-implantation to 12 months post-activation
Characterization of four-point nested impedances and monopolar impedance of the CI622D and CI622
Lasso di tempo: Activation, 12 months post-activation

Group mean impedance measured across the active electrodes for four-point nested impedance and MP1+2 impedance for the CI622D and CI622

Activation, 12 months post-activation
Characterization of mean estimated sound processor battery life for CI622D and CI622
Lasso di tempo: 12 months post-activation

The estimated sound processor battery life (hours per day) as calculated by the programming software

12 months post-activation
Difference in mean within-subject changes in global score on the Speech, Spatial, and Qualities of Hearing Scale (SSQ12) between CI622D and CI622
Lasso di tempo: Pre-implantation to 12 months post-activation

Speech, Spatial, and Qualities of Hearing Scale global score (SSQ-12). Scores range from 0 to 10, where higher scores indicate greater ability (less hearing disability).

Pre-implantation to 12 months post-activation
Difference in mean within-subject changes in global Health Utilities Index III (HUI3) between CI622D and CI622
Lasso di tempo: Pre-implantation to 12 months post-activation

Health Utilities Index (HUI 2/3) global score. Scores range from -0.36 to 1.00, where a negative score represents a state "worse than dead" and a top score of 1.00 is "perfect health".

Pre-implantation to 12 months post-activation

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Antje Aschendorff, University Hospital Freiburg

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

17 giugno 2024

Completamento primario (Effettivo)

5 novembre 2025

Completamento dello studio (Effettivo)

6 maggio 2026

Date di iscrizione allo studio

Primo inviato

16 maggio 2024

Primo inviato che soddisfa i criteri di controllo qualità

16 maggio 2024

Primo Inserito (Effettivo)

22 maggio 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

8 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi